15 - Valent Pneumococcal Conjugate Vaccine (VAXNEUVANCE™)
Highlights:
- According to the recommendation made by the Scientific Committee on Vaccine Preventable Diseases (SCVPD) under the Centre for Health Protection of the Department of Health (DH), VAXNEUVANCE™ induces high immunogenicity against serotype 3 which is believed to be more effective in preventing IPD caused by this serotype.
- It is approved for use by the US FDA and the EU, and is widely used in European and American countries such as the US, the UK and Canada, as well as Australia.
- This is a registered pharmaceutical product approved by the Pharmacy and Poisons Board of Hong Kong. It meets the criteria for safety, efficacy, and quality.
How:
- Intramuscular Injection
- Single-dose / multiple-doses administration (where applicable)
Recommended for
- Individuals aged 6 weeks or above and under 2 years old:
Standard Regimen* (2 primary doses + 1 booster dose)
- First primary dose at 2 months of age
- Second primary dose at 4 months of age
- One booster dose at 12 months of age
* A catch-up schedule is to be followed for any missed or delayed doses. Please consult a medical practitioner for the applicable schedule of vaccine administration.
- Individuals aged 2 years old or above: Single Dose
Recommended for
Individuals aged 6 weeks or above